Probiotics for Depressive Symptomatology and Neural Activity. (PRODAN)

June 19, 2026 updated by: Daniel Lamport, University of Reading

The Acute and Chronic Effects of Ecologic® Barrier on Depressive Symptoms and Neural Activation.

This study aims to investigate the acute and chronic effects of 16-week probiotic supplementation (Ecologic® Barrier) on depressive symptoms and neural activity in those with mild-to-moderate depression.

Study Overview

Detailed Description

This study will use a randomised, double-blind, placebo-controlled design. A total of 76 participants will be recruited and will receive either one sachet of the probiotic (Ecologic® Barrier) or one sachet of a placebo, matched in taste, smell, appearance, and packaging. Outcomes will be measured at baseline, 24 hours, and at 16 weeks for all participants. These include measures of general mood, depressive symptoms, executive function, and neural activity. Neural activation will be measured using electroencephalography (EEG), specifically measuring the P300 event-related potential (ERP) during an n-back task. In addition to the n-back task, executive function, specifically working memory and cognitive flexibility will be tested using the task-switching task.

The main question this study aims to answer is:

  • Does probiotic supplementation result in improvements in the primary outcome measure of vulnerability and sensitivity to depression, as well as secondary measures of rumination, hopelessness/suicidality, acceptance/coping, aggression, control, and risk aversion?
  • Does probiotic supplementation improve accuracy and response times in executive function and working memory, measured by the Task Switching Task (TST) and n-back task?
  • Is probiotic supplementation associated with an increased P300 amplitude and shorter P300 latency compared to baseline measures during the n-back task, in parietal and frontal lobe regions, with more pronounced effects in the 2-back task?
  • Is probiotic supplementation associated with changes in alpha and theta band activity and symmetry, particularly after completing a demanding working-memory task?

Study Type

Interventional

Enrollment (Estimated)

76

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • London, United Kingdom, RG6 6UR
        • School of Psychology and Clinical Languages
        • Contact:
        • Sub-Investigator:
          • Vanessa Sofia Amaral Lopes Simoes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Mild to moderate depression symptoms (BDI-II 12-28)
  • Males and females
  • Age range will be 25-40 years
  • Right-handed participants only (required for EEG)

Exclusion Criteria:

  • Taking antidepressants (up to 2 months prior to inclusion)
  • Undergoing psychological treatment in the form of counselling, therapy or similar (up to 1 month prior to inclusion)
  • Any diagnosed chronic medical condition (e.g. diabetes) or psychiatric illness.
  • Use of antibiotics or laxatives (up to 3 months prior to inclusion)
  • Use of probiotics and/or prebiotics (up to 1 month prior to inclusion)
  • Enrolled in any other clinical trial (up to 1 month prior to inclusion)
  • Following restrictive and/or unbalanced diets
  • Smoking
  • Continuous use of a weight-loss medication for more than one month prior to screening
  • Significant gastrointestinal conditions affecting absorption, including but not limited to: inflammatory bowel disease; total colectomy or bariatric surgery; irritable bowel disease; end-stage renal disease; active cancer or cancer treatment within the past three years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ecologic® Barrier
Participants will consume one sachet of Ecologic® Barrier powder(1x10^10 CFU/day), mixed in warm water with a meal. The sachets can be stored at room temperature.
Ecologic® Barrier (1x1010 CFU/day).
Other Names:
  • Probiotics
Placebo Comparator: Placebo powder

A placebo matched for packaging, visual appearance, smell, and taste will be given.

Similar to the instructions on how to take the probiotic, subjects will consume one sachet per day, kept at room temperature, mixed into warm water with a meal.

Matched placebo
Other Names:
  • placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Leiden Index of Depression Sensitivity - Revised (LEIDS-R) vulnerability/sensitivity for depression.
Time Frame: Baseline and 16 weeks
A standardised measure of cognitive reactivity. This questionnaire consists of 34 items, in which participants rate on a scale from 0 to 4, how strongly they feel each statement relates to them when they feel somewhat sad.
Baseline and 16 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Leiden Index of Depression Sensitivity - Revised (LEIDS-R). The following subscales are of interest: rumination, hopelessness/suicidality, acceptance/coping, aggression, control, and risk aversion.
Time Frame: Baseline, 24 hours, and 16 weeks
A standardised measure of cognitive reactivity. This questionnaire consists of 34 items, in which participants rate on a scale from 0 to 4, how strongly they feel each statement relates to them when they feel somewhat sad.
Baseline, 24 hours, and 16 weeks
Beck Depression Inventory (BDI-II)
Time Frame: Screening, baseline, 24 hours, and 16 weeks
A robust tool consisting of 21 items used to measure the severity of depression. It focuses on symptoms experienced in the last 2 weeks, such as cognitive and affective symptoms.
Screening, baseline, 24 hours, and 16 weeks
Mini-International Neuropsychiatric Interview (MINI)
Time Frame: Baseline, 24 hours, and 16 weeks
A short diagnostic interview designed to screen for 17 psychiatric disorders and the risk of suicide.
Baseline, 24 hours, and 16 weeks
Rumination Response Scale (RRS)
Time Frame: Baseline, 24 hours, and 16 weeks
A self-report questionnaire measuring the tendency to focus on negative thinking, distressing symptoms, and their causes when people feel down, sad, or depressed.
Baseline, 24 hours, and 16 weeks
Neural Activity
Time Frame: baseline, 24 hours, and 16 weeks

P300 event-related potential (ERP) amplitude and latency during the n-back task. Resting-state and active-state alpha and theta power oscillations.

An exploratory measure of the N2 ERP may be analysed alongside the P300.

baseline, 24 hours, and 16 weeks
Task-switching Task
Time Frame: Baseline, 24 hours, and 16 weeks
This is a measure of executive function and sustained attention. Participants will be shown a circle with 8 equally spaced radii, 2 of which form a bold bisecting line. Numbers are chosen randomly from a set of 1-4 & 6-9 and displayed sequentially in a clockwise direction. A response of higher or lower than 5 is made for trials below the line, and a response of even or odd for numbers above the line. Accuracy and reaction time (RT) on correct trials, as well as accuracy and RT on trials where there is a 'switch cost' from stimuli moving from below to above the bold line and vice versa, are the main outcome measures.
Baseline, 24 hours, and 16 weeks
N-back task
Time Frame: baseline, 24 hours, and 16 weeks
This is an executive function and working memory task. There are varying difficulties of this task, but this trial will use the 0-back and 2-back versions. The 0-back task involves participants being shown a sequence of letters and having to respond when the current letter matches that of the previous letter. In the 2-back task, participants will have to respond when the current letter matches the letter from two trials ago.
baseline, 24 hours, and 16 weeks
Profile of Mood States short form (POMS-SF)
Time Frame: Baseline, 24 hours, and 16 weeks
This is a condensed self-report questionnaire used to measure changes in mood, assessed across 6 sub-scales (tension-anxiety, depression-dejection, anger-hostility, vigour-activity, fatigue-inertia, and confusion-bewilderment) with 40 total items. A total mood disturbance score is provided.
Baseline, 24 hours, and 16 weeks
Visual Analogue Scale (VAS) of Positive and Negative feelings
Time Frame: Every day from baseline to the final 16-week time point.
Visual Analogue Scale of positive/negative feelings via a daily assessment. This includes two questions asking participants to rate on a scale from 0 to 100 the extent to which they felt positive or negative feelings.
Every day from baseline to the final 16-week time point.
Quality of Life (SF12)
Time Frame: Baseline, 24 hours, and 16 weeks
The Quality of Life (SF12) is a questionnaire which asks for participants' views about their health. This information keeps track of how they feel and how well they can do their usual activities.
Baseline, 24 hours, and 16 weeks
Gastrointestinal Symptom Rating Scale (GSRS)
Time Frame: Baseline, 24 hours, and 16 weeks
This is a 15-item self-reported questionnaire assessing the severity of gastrointestinal symptoms. It uses a 7-point Likert scale, covering five symptom domains: reflux, abdominal pain, indigestion, diarrhoea, and constipation symptoms.
Baseline, 24 hours, and 16 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Generalised Anxiety Disorder-7 (GAD-7)
Time Frame: Baseline
This is a self-report questionnaire used to measure the severity of generalised anxiety disorder. It has seven items and asks individuals to rate the frequency of anxiety symptoms over the past two weeks, with scores ranging from 0 to 21 to determine anxiety levels. Baseline scores may be used as a covariate.
Baseline
Menstrual Cycle Data
Time Frame: Baseline and 16 weeks
Information regarding the first day of the most recent menstruation, regularity and contraception will be recorded. It is not a direct outcome measure, but data may be used as a covariate.
Baseline and 16 weeks
Epic-Norfolk Food Frequency Questionnaire (FFQ)
Time Frame: Baseline and 16 weeks
This is a validated tool for analysing the average habitual dietary intake of micro and macronutrients of an individual in the UK, which is particularly important to explore in order to understand how the probiotic supplement may interact with diet and gut microbiome diversity. Data will be processed using the FETA software.
Baseline and 16 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

March 1, 2027

Study Registration Dates

First Submitted

June 19, 2026

First Submitted That Met QC Criteria

June 19, 2026

First Posted (Actual)

June 25, 2026

Study Record Updates

Last Update Posted (Actual)

June 25, 2026

Last Update Submitted That Met QC Criteria

June 19, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mild-to-moderate Depression

Clinical Trials on Ecologic® Barrier

3
Subscribe